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Abstract
Purpose In this study, the formation of cisplatin-DNA
adducts after concurrent cisplatin-radiation and the rela-
tionship between adduct-formation in primary tumor tissue
and normal tissue were investigated.
Methods Three intravenous cisplatin-regimens, given
concurrently with radiation, were studied: daily low-dose
(6 mg/m2) cisplatin, weekly 40 mg/m2, three-weekly
100 mg/m2. A 32P-postlabeling technique was used to quan-
tify adducts in normal tissue [white blood cells (WBC) and
buccal cells] and tumor.
Results Normal tissue samples for adduct determination
were obtained from 63 patients and tumor biopsies from 23
of these patients. Linear relationships and high correlations
were observed between the levels of two guanosine- and
adenosine–guanosine-adducts in normal and tumor tissue.
Adduct levels in tumors were two to Wve times higher than
those in WBC (P < 0.001). No signiWcant correlations were
found between adduct levels in normal tissues and primary
tumor biopsies, nor between WBC and buccal cells.
Conclusions In concurrent chemoradiotherapy schedules,
cisplatin adduct levels in tumors were signiWcantly higher
than in normal tissues (WBC). No evidence of a correlation
was found between adduct levels in normal tissues and pri-
mary tumor biopsies. This lack of correlation may, to some
extent, explain the inconsistencies in the literature regard-
ing whether or not cisplatin-DNA adducts can be used as a
predictive test in anticancer platinum therapy.
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Introduction
Concurrent chemoradiotherapy is more eVective than radio-
therapy (RT) alone, both in in vitro studies [1, 2] as well as
in clinical studies in many diVerent tumor types, including
advanced head and neck squamous cell carcinoma
(HNSCC) and cervical cancer, leading to improvements in
locoregional control and/or survival [11, 13, 21, 28]. In a
metaanalysis on concurrent chemoradiation in HNSCC, the
addition of concurrent single agent cisplatin to RT was the
most eVective treatment regime with the largest improve-
ment on overall survival [5]. Concurrent cisplatin-based
chemoradiation is now considered standard care in
advanced-stage HNSCC and cervical cancer.
In addition to the increased eYcacy of the combined
treatment, it was shown that the concurrent regimens are
accompanied by higher acute toxicity rates compared to
radiation alone [11, 21], with more severe mucositis and
gastrointestinal toxicity.
Since a substantial number of patients treated with con-
current chemoradiation still fail to respond to this toxic
treatment, there is a need for an accurate predictive assay,
based on which patients that are likely to respond to the
therapy can be selected. This strategy may also provide a
tool to individualize and tailor treatment, based on evalua-
tion of the predictive assay, early during therapy.
One potential predictive marker is the formation of cis-
platin-DNA adducts, which are formed when cisplatin
reacts with the cellular DNA by binding to nucleotides. The
majority of adducts are either intrastrand adducts with cis-
platin bound between two guanosine (GG) nucleotides or
adenosine–guanosine (AG) nucleotides [8]. Cisplatin-DNA
adducts can be measured in tumor and normal tissue. The
level of adducts has been shown to correlate with cyto-
toxicity in vitro [34], and with response to therapy in
patients [3, 17, 32, 35]. In most of these studies [3, 32, 35],
adduct measurements were performed in the normal tissue,
with the assumption that normal tissue can be used as surro-
gate marker for tumor.
In our institute, study protocols with cisplatin-DNA
adduct measurements are ongoing in patients with HNSCC
and cervical cancer, who are all treated with concurrent cis-
platin-based chemoradiation. The objectives of the current
study are (1) to investigate the two major forms of cis-
platin-DNA adducts (GG and AG adducts) after diVerent
schedules of cisplatin given concurrently with radiation and
(2) to explore relationships between adducts in primary
tumor and normal tissue. We speciWcally wanted to investi-
gate whether the level of adducts in tumors are reXected by
those in normal tissues. In studies focused on the predictive
value of cisplatin-DNA adduct levels, this would then
justify the use of more easily obtained normal tissues as a
surrogate for tumor samples.
Patients and methods
Concurrent chemoradiation protocols
This study on adduct formation was approved by the medi-
cal ethical committee of the participating hospitals. The
main eligibility criteria were: patients scheduled for cis-
platin chemoradiation, no previous treatment with cisplatin,
and informed consent. Eligible patients were informed
about the nature of the protocol and after written informed
consent they were entered in the study. Patients were
recruited from one of the following regimens.
In advanced-stage HNSCC patients, two diVerent
cisplatin-based concurrent chemoradiation protocols
(RADPLAT) were used. The RADPLAT 100 schedule,
which is the most commonly administered schedule in
HNSCC [11], consisted of cisplatin given intravenously
(IV) at a dose of 100 mg/m2, as a 30 min infusion, 1–2 h
before RT at days 1, 22, and 43 of treatment. This treatment
was part of a randomized trial on IV vs. intra-arterial
chemoradiation. In RADPLAT daily LD, low-dose (LD) cis-
platin was given as a 1–2 min IV infusion at a dose of 6 mg/
m2 daily, for a total number of 20 doses, 1–2 h prior to RT.
This treatment was shown to be an eVective alternative in
HNSCC [6, 19]. Patients ineligible for or refusing the ran-
domized trial on intra-arterial chemoradiation were treated
with RADPLAT daily LD, since this treatment could be
given on an outpatient basis. The RT target volumes for all
schedules included the primary tumor and the bilateral neck
at a dose of 46 Gy in 23 fractions. A boost was given to the
macroscopic tumor extensions at the primary tumor site and
lymph node metastases at a dose of 24 Gy in 12 fractions,
resulting in a total dose of 70 Gy in 35 fractions.
In patients with advanced-stage squamous cell cervical
cancer, concurrent chemoradiation (CERVIX 40) consisted
of weekly administration of cisplatin IV as a 4-h infusion at
a dose of 40 mg/m2, followed by RT within 1–2 h. The total
number of doses was 5–6, depending on external beam RT
schedule and the number of intracavitary brachytherapy
applications. The total radiation dose was usually 46 Gy to
the cervical tumor, uterus, and pelvic lymph nodes, with a
boost to the cervix tumor and other involved regions, to a
total dose of 60–74 Gy, depending on treated volume and
whether or not intracavitary brachytherapy was given.
Cisplatin-DNA adducts
Before and after chemotherapy, normal tissue samples
[white blood cells (WBC) and buccal cells] were collected.
In patients with an accessible primary tumor, a biopsy of the
tumor was also taken. To avoid harvesting necrotic tissue,
the biopsy was taken at the viable peripheral rim of the
tumor. Samples were obtained at diVerent times, due toCancer Chemother Pharmacol (2008) 61:1075–1081  1077
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logistic reasons: for the patients in the RADPLAT 100
study, this was done 23 h after the end of administration of
the Wrst cisplatin infusion (given on day 1 of treatment). In
the patients in the CERVIX 40 study, samples were taken
20 h after the end of administration of the Wrst weekly cis-
platin infusion (given on day 1 of treatment). For the
patients in the RADPLAT daily LD group, samples were
taken 1 h after the 5th dose on day 5 of treatment. WBC
were isolated from whole blood samples according to a pre-
viously published protocol [24]. Buccal cells were collected
in phosphate-buVered saline by scraping the bilateral buccal
mucosa using a cotton swab. In HNSCC patients, the buccal
mucosa could be located within the RT treatment Welds,
depending on the tumor site. The harvested cells were cen-
trifuged (5 min at 4°C, 1,000 rpm) and resuspended in a
Tris–EDTA buVer and stored at ¡80°C until analysis.
Tumor biopsies were taken and immediately frozen at
¡80°C until analysis. QuantiWcation of GG- and AG-intra-
strand adducts was performed by a 32P-postlabeling tech-
nique as previously described [29]. Internal standardization
was incorporated in the present analysis method, by adding
300 fmol of TT nucleotides to each sample. From previous
work, the reproducibility of the assay is known by analysis
of duplicate specimens within the same experiment (within-
run reproducibility) and by analysis of duplicate specimens
in separate experiments (between-run reproducibility) [29].
The reproducibility was described for WBC and tumor sam-
ples and was within 10% for the within-run precision and
between 2–20% for the between-run precision. It was also
determined for buccal cells in the same way and similar
reproducibility was obtained. The concentration of DNA
present in the samples was measured spectrophotometri-
cally at 260 nm with the Nanodrop ND-1000 (Nanodrop
Technologies Inc, Wilmington, DE, USA). The cisplatin-
DNA adduct levels were expressed as fmol/g DNA. The
lower limit of quantiWcation for the Pt-GG and Pt-AG
adducts was 0.087 and 0.053 fmol/g DNA, respectively.
Statistical analysis
Analysis of data was performed in SPSS software (version
11.5, SPSS, Inc.). For quantitative comparison of numerical
data between groups, the Student’s t-test was applied. The
Pearson correlation coeYcient and Spearman’s rank corre-
lation coeYcient were calculated for analysis of correla-
tions between diVerent samples (WBC, buccal cells, and
primary tumor) on an intra-patient level.
Results
Samples for cisplatin-DNA adduct determination were
obtained from 63 patients: 27 from RADPLAT daily LD,
15 from CERVIX 40, and 21 from RADPLAT 100. WBC
samples were taken from 61 patients, buccal cells from 25,
and tumor biopsies from 23 of these patients. The reasons
for the missing data for the normal tissue samples were: no
collection of samples due to logistics or (in minority of
cases) not suYcient volume for analysis. The reason for
missing primary tumor biopsy data were: tumor not acces-
sible for direct outpatient-based biopsy (in HNSCC
patients) or refusal (in cervix cancer patients).
In WBC, all but three of the 60 available baseline sam-
ples were below the LLQ for the GG adducts and all but
two below the LLQ for the AG adducts. This was proba-
bly due to some background signal inherent in the postla-
beling method, since all patients had not been treated
before with platinum chemotherapy. The yield of DNA,
obtained from the buccal cell samples was rather low,
ranging from 1–10 g. Baseline samples of buccal cells
were available from 16 of 25 patients, of whom posttreat-
ment samples were also available. The baseline values of
GG adducts in buccal cells ranged from 0.067 to
0.745 fmol/g DNA (mean 0.282, SD 0.19) and baseline
values of AG adducts in buccal the cells ranged from
0.087 to 1.538 fmol/g DNA (mean 0.398, SD 0.38). All
but two of the baseline GG-adduct values were above the
LLQ and all the baseline AG-adduct values were above
the LLQ. This was probably due to the low DNA quanti-
ties obtained from the buccal cell samples. The diVerence
in adduct levels from baseline to post-infusion values was
signiWcant for the GG adducts, but not for the AG
adducts. This implies that for measuring low quantities of
AG adducts in the low amounts of buccal cell DNA avail-
able, we reached the limits of quantiWcation with this
postlabeling method.
In Table 1, the results are presented for the GG- and
AG-adduct levels in normal tissue and primary tumor for
the three diVerent cisplatin-chemoradiation regimes.
Adduct levels in primary tumor were two to Wve times
higher than those in WBC for all three treatment regimes
for both GG- and AG-adduct formation (Student t-test,
P < 0.001 for both adduct types). For the comparison of the
adduct levels from the three diVerent treatment protocols,
the data from the RADPLAT daily LD were omitted, since
the daily administration schedule and sampling time (1 h
after the infusion) were diVerent from the other two regi-
mens. The adduct levels in the RADPLAT 100 schedule
were statistically signiWcantly higher than those after the
CERVIX 40 schedule for both tumors (Student t-test,
P = 0.01) and normal tissues (Student t-test, P <0 . 0 1 ) .
A highly signiWcant linear correlation (Pearson correla-
tion, r =0 . 9 3 ,   P <0.001, n = 61) was observed between the
level of GG and AG adducts in WBC (see Fig. 1a), with a
mean ratio of GG/AG adducts of 7.6 § 2.1 SD. Similar
linear relationships and ratios were found for GG and AG1078 Cancer Chemother Pharmacol (2008) 61:1075–1081
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adducts in primary tumor (r =0 . 8 9 ,   P < 0.001, n =2 3 ,  a n d
ratio 8.5 § 2.8; Fig. 1b) and buccal cells (r =0 . 8 5 ,
P < 0.001, n = 23, and ratio 3.9 § 1.3; Fig. 1c).
A trend was observed between GG-adduct levels in
WBC and buccal cells, although not signiWcant (r =0 . 3 8 ,
P =0 . 0 7 ,  n =2 4 ) .  N o  s i g n i Wcant correlations were found
between tumor and normal tissue: tumor vs. WBC
(r =0 . 3 5 ,  P = 0.13,  n = 21) and tumor vs. buccal cells
(r = ¡0.003, P =0 . 9 9 ,  n = 9). See Fig. 2 for scatter plots.
Similar results were found for the AG adducts: no signiW-
cant correlations were found between adducts in tumor vs.
WBC (r = 0.14, P =0 . 5 5 ,  n = 21), tumor vs. buccal cells
(r =0 . 2 5 ,   P =0 . 5 8 ,   n = 7) or WBC vs. buccal cells
(r =0 . 2 6 ,   P =0 . 2 4 ,   n = 22).
Discussion
There are two main conclusions from the 63 patients
included in these analyses. First, intra-tumoral adduct lev-
els were substantially higher than those in normal tissue
(WBC) at all cisplatin-dose levels examined. Second, no
positive correlations were evident between adducts in
tumors and normal tissues. It should be noted that the vari-
ous schedules, the cisplatin doses, and the duration of infu-
sions diVered, as well as the sampling times. However, all
analyses on adducts were performed on paired samples,
within the same patient. This eliminates variance of these
factors since the normal tissue and tumor samples all were
obtained at similar time points after the cisplatin infusion.
In the RADPLAT daily LD, some accumulation from the
previous four daily 6 mg cisplatin infusions would have
occurred and aVected the day 5 measurement after the 5th
Table 1 Cisplatin-DNA adducts (in fmol/g DNA) in normal tissue
and primary tumor after diVerent schedules of cisplatin-based chemo-
radiation
See text for explanation of treatment schedules
N number of patients, SD standard deviation, WBC white blood cells,
GG GG-adducts, AG AG adducts
Treatment 
schedule
WBC Buccal cells Tumor
GG AG GG AG GG AG
RADPLAT daily LD
N 26 26 11 11 6 6
Mean 0.34 0.05 0.84 0.21 0.66 0.10
SD 0.10 0.19 0.39 0.14 0.37 0.05
CERVIX 40
N 1 4 1 4 771 0 1 0
Mean 0.44 0.06 0.87 0.22 1.94 0.26
SD 0.17 0.03 0.26 0.06 1.47 0.26
RADPLAT 100
N 2 1 2 1 7777
Mean 1.047 0.124 1.563 0.340 3.866 0.413
SD 0.377 0.049 0.434 0.090 1.101 0.089
Fig. 1 Correlation-plots of GG- and AG-adduct levels in white blood
cells (WBC) (panel a), primary tumor biopsy (panel b), buccal cells
(panel c). In each panel, the three diVerent treatment groups are depict-
ed: RADPLAT daily LD 5 £ 6 mg (red squares), CERVIX 40 mg
(green circles), and RADPLAT 100 mg (blue triangles)
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infusion. In the RADPLAT 100 and CERVIX 40 patients,
no such accumulation would have occurred, since the sam-
pling was done 20–23 h after the Wrst infusion of cisplatin.
Relatively little information is available regarding the
in vivo formation of intra-tumoral cisplatin-DNA adducts
in clinical series [17, 23]. Most studies focused on intra-
tumoral platinum concentrations, both in HNSCC [12, 33]
and cervical cancer patients [15,  22]. These studies are
mostly characterized by relatively low numbers of patients,
probably due to the invasive nature of the procedure. The
data on correlations between adducts and platinum content
are contradictory: In an experimental study [37], no rela-
tionship could be established between the intra-tumoral
adduct levels and platinum content, although in one clinical
study, a signiWcant correlation was found [23].
Adduct levels in primary tumors were consistently two-
to Wvefold higher than in WBC. This was true for both GG
and AG adducts. This Wnding was previously described in
anecdotal clinical cases [9, 30]. Similar observations were
made in platinum content studies in an experimental tumor
model [18] and in HNSCC patients [33]. Adducts in tumor
were also higher than in buccal cells in the CERVIX 40 and
RADPLAT 100 group, but not in the RADPLAT daily LD
group. We observed a linear relationship between the two
major adduct forms (AG and GG) for both normal tissues
and tumor (Fig. 1a–c), although GG-adduct formation was
5–12 times increased relative to the AG adducts, as
reported earlier [8, 36]. The linear relationships between
GG and AG adducts serve as a validation of the assay.
Apparently within a sample, both types of adducts are pres-
ent in an equal proportion, although the absolute amounts
diVer greatly. In previous studies, the type of adduct
responsible for the cytotoxic eVect of platinum compounds
has been investigated. From two of these studies [7, 36] it
was concluded that the AG adduct was responsible for the
platinum cytotoxicity. From our study, such a conclusion
cannot be made, since both types of adducts were present in
equal proportions.
Adduct formation in diVerent tissue samples showed a
lack of correlation between tumor and normal tissue. One
might have expected that higher adduct levels in normal tis-
sue would be accompanied by more adducts in tumor,
although this was not the case. Similar results were found
in an animal study [25] and in a clinical series of uterine
cervix cancer patients [22], both demonstrating lack of cor-
relation between tumor platinum and serum platinum con-
centrations. If adduct formation were merely a matter of
cisplatin exposure, then a positive correlation would be
expected. The reasons for the higher levels of adducts in
tumor vs. normal tissue and the lack of correlation between
them may be explained by diVerences between tumor and
normal tissue in one of the following factors: Tumors are
heterogeneous in terms of blood supply and perfusion,
resulting in diVerences in cisplatin uptake and diVusion,
drug-pumps may diminish intra-cellular cisplatin concen-
trations by active transmembrane transport of cisplatin,
Fig. 2 Correlation plots of GG adducts in white blood cells (WBC) vs.
buccal cells (panel a), and normal tissue vs. tumor (panels b and c). In
each panel, the three diVerent treatment groups are depicted: RAD-
PLAT daily LD 5 £ 6m g  ( red squares), CERVIX 40 mg (green cir-
cles), and RADPLAT 100 mg (blue triangles)
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prohibiting adducts to be formed, and tumor cells may have
less eVective capacities to repair damage from cytotoxic
agents.
Adducts are formed rapidly and in a dose-dependent
fashion within 1–2 h after cisplatin exposure, with a grad-
ual decrease (repair) within the next 20–24 h [20, 32, 36].
The persistence of cisplatin-DNA adducts may therefore be
regarded as a measure of repair and possibly be used as pre-
dictive assay. We therefore chose to measure adducts
20–23 h after the end of chemotherapy infusion. Ideally,
more frequent measurements would have generated more
information on the rate of adduct formation, repair, and
total exposure to adducts (like an AUC analysis) [24].
However, obtaining repeated biopsies is not feasible in clin-
ical practice.
The results from the buccal cell samples need to be inter-
preted with caution, especially the AG-adduct levels, since
uncertainties remain. With the low quantities of AG-
adducts in the low amounts of buccal cell DNA we could
extract, we reached the limits of quantiWcation of the post-
labeling method.
The rationale for measuring cisplatin-DNA adducts is
that it could be used as a predictive assay: higher levels of
adducts would predict favorable treatment outcome. Many
studies have been performed for this purpose, investigating
adducts in normal tissue (WBC and buccal cells) [3, 4, 10,
14, 26, 31, 32, 35]. These study designs are based on the
assumption that normal tissue can be used as a surrogate
marker for tumor tissue with respect to cisplatin-DNA
adduct formation. In our present study, however, we did not
Wnd such a correlation. This might explain why the results
on the role of adduct formation to predictive outcome are
heterogeneous and contradictory, as illustrated below.
Several studies on adduct formation in WBC showed
that the level of adducts was positively correlated with
response to chemotherapy in patients with advanced dis-
ease in a variety of tumor sites [31,  32], while others
showed no correlation [4, 26]. One study showed a positive
correlation in one tumor site (ovarian cancer), but not in the
other (breast cancer) [14], and in another study the level of
adduct formation showed a negative association with sur-
vival for day-5 adducts, while there was no diVerence for
day-1 adducts [10]. In studies on adduct levels in buccal
cells, a positive correlation was found between adducts and
either disease response [3] or better survival in non-small
cell lung cancer (NSCLC) [35]. We recently showed that
adduct formation in primary tumor appeared to be associ-
ated with better progression-free survival in HNSCC [17].
DiVerences were observed between the levels of intra-
tumoral adducts for the three chemoradiation schedules,
with lower adducts after lower dosages of cisplatin. Based
on this, however, one cannot predict that the schedules with
less adducts will result in less cytotoxicity, since not only
the cisplatin dose, but also timing and schedule of cisplatin
administration are crucial determinants of eYcacy [1].
These factors may contribute to diVerences in the formation
and rate of repair of adducts, resulting in diVerent expo-
sures to cisplatin-DNA adducts. These diVerences make it
diYcult to extrapolate from the observed adduct values in
tumor and normal tissues to a prediction of superiority of
one schedule over another.
In future studies, immunohistochemistry on repair pro-
teins like ERCC1 [27] or gene expression proWling studies
on platinum resistance [16] could be used to improve the
prediction of cisplatin sensitivity and prediction of therapy
response.
In conclusion, we have demonstrated that in concurrent
chemoradiotherapy schedules, cisplatin adduct levels in
tumors were signiWcantly higher than in normal tissues
(WBC). No evidence of a correlation was found between
adduct levels in normal tissues and primary tumor biopsies.
This lack of correlation may, to some extent, explain the
inconsistencies in the literature regarding whether or not
cisplatin-DNA adducts can be used as predictive test in
anticancer therapy.
ConXict of interest: none declared.
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